Residency · Residency · Radiation Oncology
Salivary Gland Tumors and Neutron/Proton Therapy Considerations
Overview
Salivary gland malignancies represent approximately 3-5% of all head and neck cancers. The major salivary glands include the parotid, which accounts for 70-80% of tumors, the submandibular gland with 10-15%, and the sublingual gland, where tumors are rare. Minor salivary glands are distributed throughout the oral cavity, oropharynx, nasal cavity, paranasal sinuses, and larynx. These tumors exhibit a diverse histologic spectrum with over 20 subtypes, each demonstrating widely varying biological behavior. Surgery remains the primary treatment modality, while radiation therapy serves an important adjuvant role, particularly for high-risk features and unresectable disease. A hallmark of salivary gland malignancies is perineural invasion (PNI), especially along named cranial nerves, which significantly influences radiation target delineation.
Histologic Classification
Mucoepidermoid Carcinoma
Mucoepidermoid carcinoma is the most common salivary gland malignancy, comprising 30-35% of cases. It is graded as low, intermediate, or high grade. Low-grade tumors have an excellent prognosis, with over 90% cure rates achieved by surgery alone, and thus adjuvant radiation therapy plays a limited role. In contrast, high-grade mucoepidermoid carcinoma behaves aggressively, similar to high-grade squamous cell carcinoma, with frequent nodal metastasis and distant failure.
Adenoid Cystic Carcinoma (ACC)
Adenoid cystic carcinoma is the second most common salivary gland malignancy, accounting for about 20-25% of cases. It is characterized by a distinctive pattern of perineural invasion, often tracking along named cranial nerves such as the facial nerve (cranial nerve VII) in parotid tumors and the trigeminal nerve (cranial nerve V) in minor salivary gland tumors. ACC has an indolent but relentless natural history, with late local recurrences occurring 10-20 years after treatment and distant metastases, most commonly to the lungs. Histologically, ACC presents in three patterns: tubular, which has the best prognosis; cribriform, with intermediate prognosis; and solid, which carries the worst prognosis. Due to its perineural spread, ACC often results in high rates of positive or close surgical margins.
Acinic Cell Carcinoma
Acinic cell carcinoma predominantly arises in the parotid gland and generally has a favorable prognosis, as most tumors are low grade. Adjuvant radiation therapy is considered for high-risk features such as close surgical margins or high-grade transformation.
Salivary Duct Carcinoma
Salivary duct carcinoma is an aggressive, high-grade malignancy that histologically resembles ductal carcinoma of the breast. It is associated with high rates of nodal and distant metastasis. Approximately 30% of these tumors overexpress HER2, and androgen receptor positivity is common. Treatment typically involves adjuvant radiation therapy combined with systemic therapy.
Adenocarcinoma NOS, Polymorphous Adenocarcinoma, and Others
These tumors exhibit varied behavior, and treatment decisions depend on factors such as histologic grade, stage, and surgical margins.
Indications for Adjuvant Radiation Therapy
Certain clinical and pathological features definitively indicate the need for adjuvant radiation therapy. These include high-grade histology, such as high-grade mucoepidermoid carcinoma, salivary duct carcinoma, and high-grade adenocarcinoma. Positive or close surgical margins, perineural invasion—especially involving named nerves—T3 or T4 primary tumors, lymph node metastases, and most cases of adenoid cystic carcinoma due to its high local recurrence rates also warrant adjuvant radiation.
Relative indications for adjuvant radiation include intermediate-grade mucoepidermoid carcinoma with close margins, lymphovascular invasion, and deep lobe parotid tumors with close margins abutting the skull base. Conversely, observation may be appropriate for small, low-grade mucoepidermoid carcinomas that have been completely excised with wide negative margins, as well as for acinic cell carcinoma with negative margins and no high-risk features.
Radiation Therapy Technique
Dose and Fractionation
For adjuvant radiation therapy with negative margins, a dose of 60 Gy delivered in 30 fractions is standard. When positive margins or gross residual disease are present, doses escalate to 66-70 Gy over 33-35 fractions. Elective nodal coverage typically involves 50-54 Gy in 25-28 fractions. In definitive settings for unresectable tumors, 70 Gy in 35 fractions is used, often with consideration for a particle therapy boost.
Target Volume Delineation
Gross tumor volume (GTV), when applicable, includes residual or unresectable disease identified on postoperative imaging. The high-risk clinical target volume (CTV) encompasses the surgical bed plus a margin, guided by operative clips and preoperative imaging. For adenoid cystic carcinoma with perineural invasion along named nerves, the CTV must follow the involved nerve proximally toward the skull base. For example, cranial nerve VII is tracked from the parotid gland to the stylomastoid foramen, and if perineural invasion is extensive, the target extends to the internal auditory canal. Cranial nerve V involvement requires tracking from the tumor along the affected division to the corresponding foramen—ovale for V3, rotundum for V2—and further to the cavernous sinus or Meckel's cave.
Elective nodal CTV typically includes nodal levels IB through III for parotid tumors and may extend to level V for high-grade tumors. Nodal irradiation is warranted for high-grade tumors such as salivary duct carcinoma and high-grade mucoepidermoid carcinoma due to their significant nodal risk. In contrast, low-grade adenoid cystic carcinoma has a low nodal risk and can often be treated with local fields alone.
IMRT/VMAT
Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) is strongly recommended for parotid tumors to spare the contralateral parotid gland and reduce xerostomia. The complexity of target volumes, especially when including perineural tracking to the skull base, requires careful optimization. Critical structures such as the optic apparatus, temporal lobes, and brainstem must be respected during treatment planning for skull base extension.
Particle Therapy
Neutron Therapy (Historical)
Neutron therapy utilizes high linear energy transfer (LET) radiation, which causes dense ionization and more complex DNA damage. Fast neutrons have a relative biological effectiveness (RBE) of approximately 3-4. Adenoid cystic carcinoma was considered an ideal tumor for neutron therapy due to its relative radioresistance to photons. Prospective trials, including data from the University of Washington, demonstrated improved local control with neutron therapy compared to photon radiation for unresectable ACC. However, the high rates of late toxicity—such as severe fibrosis, osteoradionecrosis, and cranial neuropathy—limited its widespread adoption. Today, very few neutron therapy facilities remain worldwide, and neutron therapy has largely been replaced by proton and carbon ion approaches.
Proton Therapy
Proton therapy offers superior dose conformality due to the Bragg peak, which is particularly advantageous for tumors involving the skull base and paranasal sinuses. This allows for reduced radiation dose to adjacent critical structures like the temporal lobes, optic chiasm, brainstem, and cochlea. Proton therapy is increasingly used for ACC and other salivary gland malignancies requiring skull base coverage. The proton RBE is approximately 1.1, which limits its biological advantage over photons; thus, the primary benefit is dosimetric. Retrospective series from proton centers suggest favorable local control and reduced toxicity for skull base ACC.
Carbon Ion Therapy
Carbon ion therapy delivers high-LET radiation similar to neutrons but combines this with the dosimetric advantage of the Bragg peak. It has an RBE of about 3 in the spread-out Bragg peak, offering potential to overcome the radioresistance of ACC while maintaining dose conformality. Prospective data from centers such as the National Institute of Radiological Sciences (NIRS) in Japan and Heidelberg Ion Therapy Center (HIT) in Germany demonstrate excellent local control rates for unresectable ACC, approximately 70-80% at 5 years. However, carbon ion therapy availability is limited, with operational facilities in Japan, Germany, Italy, China, and a few other centers worldwide.
Facial Nerve Management in Parotid Surgery and Radiation Therapy
Surgical Considerations
Preservation of the facial nerve is standard practice during parotid surgery when the nerve is not directly invaded by tumor. However, sacrifice of the facial nerve is required when the tumor encases or invades the nerve, a scenario most common with high-grade tumors. Nerve grafting may be performed at the time of resection to restore function.
Radiation Planning Considerations
Radiation planning aims to avoid excessive dose to the contralateral facial nerve. When the ipsilateral facial nerve is preserved and perineural invasion is present, the nerve should be included in the radiation target volume, but with moderate dose coverage to balance tumor control and nerve preservation. If the facial nerve is sacrificed, perineural tracking of the clinical target volume remains necessary if perineural invasion is confirmed pathologically.
<image>An anatomical illustration of the parotid gland region showing the facial nerve (CN VII) coursing through the gland, dividing into its five branches (temporal, zygomatic, buccal, marginal mandibular, cervical). The superficial and deep lobes are delineated. A tumor in the deep lobe is shown with perineural invasion tracking along the main trunk of CN VII toward the stylomastoid foramen, illustrating the clinical target volume extension needed for adjuvant radiation.</image>
<image>A side-by-side comparison of dose distributions for a skull base adenoid cystic carcinoma treated with (A) IMRT photons, (B) proton therapy, and (C) carbon ion therapy. The target volume extends along the trigeminal nerve (V3) from the infratemporal fossa to the foramen ovale and Meckel's cave. Color-wash isodose lines demonstrate reduced dose to the temporal lobes, brainstem, and optic chiasm with proton and carbon ion plans compared to IMRT.</image>
<image>A Kaplan-Meier curve comparing local control rates for unresectable adenoid cystic carcinoma treated with fast neutron therapy, carbon ion therapy, and conventional photon RT. Neutron and carbon ion curves show superior local control (~65-75% at 5 years) compared to photon RT (~40-50% at 5 years), with annotations noting the higher late toxicity rates associated with neutron therapy.</image>
Key Clinical Pearls
Adenoid cystic carcinoma has a deceptive natural history; patients may appear cured at five years but can develop late local recurrences or distant metastases even 10 to 20 years after treatment, necessitating lifelong follow-up. Perineural invasion along named cranial nerves is a hallmark of ACC and directly influences radiation target volumes—always trace the involved nerve proximally toward the skull base and include this pathway in the clinical target volume. The decision to include elective nodal irradiation depends on histologic grade: high-grade tumors such as salivary duct carcinoma and high-grade mucoepidermoid carcinoma have significant nodal risk and warrant elective nodal coverage, whereas ACC has a low nodal risk (less than 5-10%) and can often be treated with local fields alone. Particle therapy, including protons and carbon ions, offers dosimetric and potentially biological advantages for skull base salivary gland tumors, with carbon ions potentially providing particular benefit for ACC due to its resistance to conventional photon radiation. Neutron therapy is largely historical now because of excessive late toxicity and limited availability, but it established the principle that high-LET radiation improves local control for radioresistant salivary gland tumors.
References
- Laurie SA et al. "Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review." Lancet Oncol. 2011;12(8):815-824.
- Laramore GE et al. "Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial." Int J Radiat Oncol Biol Phys. 1993;27(2):235-240.
- Jensen AD et al. "Carbon ion therapy for advanced adenoid cystic carcinoma of the skull base: results from a prospective phase II trial." Radiother Oncol. 2015;117(2):300-306.
- Amini A et al. "Adjuvant radiation therapy for salivary gland cancers." Head Neck. 2016;38(S1):E1431-E1437.
- Coca-Pelaz A et al. "Adenoid cystic carcinoma of the head and neck -- an update." Oral Oncol. 2015;51(7):652-661.
